Iloprost (Ventavis, BAYQ6256)

DRUG3 trials

Sponsors

Bayer

Conditions

Hypertension, Pulmonary

Unknown Phase

Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years

CompletedNCT00250640

BayerHypertension, Pulmonary

Start: 2005-04-30End: 2012-07-31Updated: 2015-02-02

Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension

CompletedNCT01971450

BayerHypertension, Pulmonary

Start: 2013-11-21End: 2018-04-18Updated: 2019-03-26

Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

CompletedNCT03293407

BayerHypertension, Pulmonary

Start: 2018-02-01End: 2020-01-20Updated: 2021-05-26

Related Papers

Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP)

Journal of Medical Internet Research2021-10-0810 citations

Evaluation of compliance of pulmonary hypertension patients to the treatment with inhaled iloprost (Ventavis): results of prospective, multicenter, non-interventional IVENT study

Systemic Hypertension2019-06-154 citations

Evaluation of Clinical Outcomes and Simultaneous Digital Tracking of Daily Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Protocol for the Observational VENTASTEP Study.

2019-04-155 citations